Table 3.
Comparison of patients who resulted in nondetectable viral loads (<20 copies/ml) and virologic failure (≥1000 copies/ml) after PLLV.
| Variables | Nondetectable | VF | P value |
|---|---|---|---|
| N = 506 | n = 451 | n = 55 | |
| Age group | |||
| 1 to 9 | 33 | 4 | 0.006 |
| 10 to 19 | 30 | 8 | |
| 20 to 24 | 10 | 4 | |
| 25 to 30 | 11 | 5 | |
| 31 to 40 | 73 | 6 | |
| 41 to 50 | 164 | 17 | |
| 51 and above | 130 | 11 | |
| Gender | |||
| Male | 206 | 22 | 0.424 |
| Female | 245 | 33 | |
| Education | |||
| None | 1 | 1 | 0.371 |
| Preschool | 13 | 2 | |
| Primary | 91 | 13 | |
| Secondary | 97 | 11 | |
| Postsecondary | 60 | 5 | |
| Not documented | 189 | 23 | |
| Marital status | |||
| Single | 93 | 18 | 0.001 |
| Married | 245 | 18 | |
| Separated/divorced | 22 | 4 | |
| Widowed | 26 | 6 | |
| Not documented | 65 | 9 | |
| Years positive | |||
| 0 to 5 | 33 | 4 | 0.96 |
| 6 to 10 | 114 | 12 | |
| 11 and above | 137 | 14 | |
| Not documented | 222 | 55 | |
| Age at HIV diagnosis | |||
| 1 to 9 | 55 | 9 | 0.002 |
| 10 to 19 | 10 | 6 | |
| 20 to 29 | 38 | 3 | |
| 30 to 39 | 104 | 6 | |
| 40 to 49 | 55 | 4 | |
| 50 and above | 18 | 2 | |
| Not documented | 171 | 25 | |
| Baseline CD4 | |||
| <500 | 74 | 11 | 0.525 |
| ≥500 | 11 | 1 | |
| Not documented | 366 | 43 | |
| Baseline WHO stage | |||
| Stage 1 | 158 | 20 | 0.424 |
| Stage 2 | 65 | 5 | |
| Stage 3 | 96 | 17 | |
| Stage 4 | 31 | 5 | |
| Not documented | 101 | 8 | |
| Baseline viral load | |||
| Nondetectable | 110 | 8 | 0.0001 |
| 20 to 199 | 213 | 10 | |
| 200 to 999 | 44 | 13 | |
| 1000 and above | 84 | 24 | |
| TB history | |||
| Yes | 62 | 12 | 0.11 |
| No | 389 | 43 | |
| OI history | |||
| Yes | 372 | 46 | 0.831 |
| No | 79 | 9 | |
| PCP | |||
| Yes | 3 | 0 | 0.544 |
| No | 448 | 55 | |
| Cryptococcal disease | |||
| Yes | 3 | 1 | 0.362 |
| No | 448 | 54 | |
| Oral candidiasis | |||
| Yes | 18 | 5 | 0.086 |
| No | 433 | 50 | |
| Kaposi's sarcoma | |||
| Yes | 1 | 0 | 0.727 |
| No | 450 | 55 | |
| Other cancers | |||
| Yes | 6 | 1 | 0.77 |
| No | 445 | 54 | |
| Hypertension | |||
| Yes | 69 | 6 | 0.387 |
| No | 382 | 49 | |
| Diabetes | |||
| Yes | 16 | 0 | 0.156 |
| No | 435 | 55 | |
| Renal disease | |||
| Yes | 16 | 3 | 0.482 |
| No | 435 | 52 | |
| IPT status | |||
| Completed | 251 | 33 | 0.106 |
| Deferred | 76 | 17 | |
| Start | 15 | 1 | |
| Continuing | 20 | 0 | |
| Declined | 9 | 0 | |
| Defaulted | 2 | 1 | |
| Not documented | 78 | 3 | |
| First VL at PLLV | |||
| 500 to 999 | 31 | 12 | 0.0001 |
| 200 to 499 | 63 | 15 | |
| 20 to 199 | 357 | 28 | |
| VL status at PLLV | |||
| Viral blips | 132 | 28 | 0.001 |
| VL ≥ 200 to 999 | 19 | 13 | |
| All VL ≤ 199 | 300 | 14 | |
| Start regimen | |||
| 2NRTI+1PI/r | 89 | 11 | 0.9333 |
| 2NRTI+1NNRTI | 350 | 43 | |
| 2NRTI+1INSTI | 12 | 1 | |
| Switched regimen at PLLV | |||
| Yes | 184 | 17 | 0.157 |
| No | 267 | 38 | |
VF: virologic failure; OI: opportunistic infection; VL: viral load; WHO: World Health Organization; IPT: Isoniazid Preventive Therapy; PCP: pneumocystis pneumonia.